PresbyopiaEPACTNCT07878416
Evaluation of Functional Superiority of the Morrow eProgressive
A study testing 3 weeks wearing of study device instead of their current wearing solution in people with Presbyopia, run by Morrow Eyewear at 3 sites in 2 countries.
Trial summary
Presbyopia is a common age-related condition where the eye loses its ability to focus on nearby objects, typically from around age 45. The standard correction is progressive addition lenses (PALs), but these have limitations: narrow viewing zones, peripheral distortion, and the need for unnatural head movements, which… Read more about this study
- Who is it for?
- Ages 45 years and older
- Conditions the study is for
- Presbyopia
- What is being tested?
- 3 weeks wearing of study device instead of their current wearing solution
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 3 sitesin 2 countries
- Study dates
- 24 Sep 2026to 28 Feb 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged 45 or older, who are presbyopic in both eyes, with an inclusion criterium of minimum + 1.75 ADDition.
- Suitable candidate for Morrow glasses
- Willing and able to adhere to the study protocol and study procedures, and provide written consent prior to enrollment
- Willing and able to strictly adhere to the 2 x 3-week spectacle-wearing schedule for all standard day-to-day activities, including a commitment to exclusive progressive wear of the assigned study spectacles (traditional PAL or Morrow eProgressive) throughout each respective study phase (temporary exceptions for sports or specific occasions are permitted using single-vision solutions only).
- Current vision solution satisfaction below 8/10, as assessed by the study specific satisfaction questionnaire.
Who cannot join
- Individuals who do not yet require a reading addition for near tasks.
- Distant BCVA worse than 20/25 (Snellen) or >0.1 LogMar
- Previous laser treatment for refractive correction.
- Any previous refraction and/or intra-ocular surgery.
- Any known systemic diseases affecting vision (e.g. diabetes, uncontrolled or unmedicated hypertension, autoimmune disease, inflammatory disease … ), at the discretion of the investigator
- Associated strabismus (eyes not properly aligned)
Show all 9Show fewer
- Associated amblyopia (lazy eye)
- Currently undergoing orthoptics therapy (exercises or treatments to fix eye movement problems or double vision)
- Associated anisometropia > 1.5 diopters
Trial locations and contacts
3 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
3 sites in 2 countries
Belgium2 sites, 2 recruiting
- Recruiting
University Hospital Antwerp
Antwerp
Carina Koppen, +3238213372, secretariaat.oogheelkunde@uza.be
- Not yet recruiting
Meclinas
Mechelen
Lisa Billast, +3215792797, info@meclinas.com
Italy1 site, 1 recruiting
- Not yet recruiting
Research Centre in Optics & Optometry (COMiB), University of Milano Bicocca
Milan
Fabrizio Zeri, +39264485054, fabrizio.zeri@unimib.it
About this study
Official title: Evaluation of Functional Superiority of the Morrow eProgressive : A Comparative Study of Visual and Physical Comfort During Dynamic Activity
Presbyopia is a common age-related condition where the eye loses its ability to focus on nearby objects, typically from around age 45.
The standard correction is progressive addition lenses (PALs), but these have limitations: narrow viewing zones, peripheral distortion, and the need for unnatural head movements, which can affect comfort and safety.
Read more
Morrow has developed an electronically adjustable progressive lens (Morrow eProgressive) that dynamically adapts its optical zones.
This CE-marked device is already commercially available. This study compares its functional performance against standard PALs.
Approximately 50 adults (≥45 years) will participate at three sites (Belgium and Italy). Each participant wears both glasses types for three weeks each, in random order.
Researchers will measure head and eye movements during reading tasks, stair descent performance, and visual comfort via a questionnaire. Participants will also indicate their overall lens preference.
Read the detailed description
Traditional PALs are characterized by fixed optical corridors bordered by lateral astigmatism. This spatial restriction imposes a significant physiological and biomechanical burden on the wearer during dynamic visual tasks. When executing lateral gaze shifts, such as shifting from the end of a line of text to the beginning of the next during reading, or scanning the ground during locomotion, wearers must either tolerate peripheral blur or employ compensatory head movements. The Morrow eProgressive utilizes active electronic focal adaptation to provide an expanded, uncompromised visual field, theoretically mitigating these optical limitations and restoring natural oculomotor patterns.
A key challenge in presbyopic clinical trials is the high degree of inter-individual variability. Factors such as individual neuro-visual adaptation speed and prior spectacle history vary widely between patients. To eliminate these significant confounding variables, this investigation utilizes a randomized, open-label, crossover design. By allowing each participant to serve as their own internal control across balanced 3-week wear periods, the study isolates the direct optical impact of the lens technology from confounding patient specific characteristics, vastly increasing the statistical validity of the intra-subject comparisons.
This study optimizes clinical efficiency by employing a dual-layered endpoint strategy:
- Objective dynamic visual performance (Primary): Eye-tracking parameter, specifically head gain, serve as objective indicator of visual field performance.
- Functional and Subjective Validation (Secondary): To ensure these micro-physiological improvements translate to real-world patient utility, objective metrics are paired with the validated Near Visual Acuity Questionnaire Presbyopia (NAVQ-P), a dedicated Subjective Lens Preference Questionnaire, and physical performance tasks via a standardized Stair Descent Test.
- Conditions
- Presbyopia
- Being tested
- 3 weeks wearing of study device instead of their current wearing solution
- Keywords
- post market, presbyopia
- Medical subject headings
- Presbyopia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
3 weeks wearing of study device instead of their current wearing solutionProcedure or surgery
Instead of wearing their current solution for presbyopia, all participants can solely wear allocated spectacles during the duration of the trial for all day to day activities.
| Study group | Role | What they receive |
|---|---|---|
| Morrow eProgressive | Experimental | 3 weeks wearing of study device instead of their current wearing solution Receives: Procedure: 3 weeks wearing of study device instead of their current wearing solution |
| Traditional PAL | Active comparator | 3 weeks wearing of study device instead of their current wearing solution Receives: Procedure: 3 weeks wearing of study device instead of their current wearing solution |
What is being measured
The primary outcome is the main question the study is designed to answer.
Reduction in head gain
Reduction in head gain: defined as the ratio of head yaw angle to total gaze angle, assessed during optotype reading across varying horizontal and vertical gaze angles, to evaluate the superiority of the Morrow eProgressive over the control Progressive Addition Lens (PAL) in facilitating more efficient gaze strategies and dynamic visual performance.
Measured: Comparing the 3-week wearing period at visit 4, with the 3-week wearing period at visit 3
Secondary outcomes (4)
Mean stair descent time
Stair Descent Performance: The change in mean stair descent time (measured in seconds) during a standardized stair descent test, compared between the Morrow eProgressive and the control Progressive Addition Lens (PAL).
Measured: Comparing the 3-week wearing period at visit 4, with the 3-week wearing period at visit 3
Mean cadence variability
Stair Descent Performance: The change in mean cadence variability (gait stability metric) during a standardized stair descent test, compared between the Morrow eProgressive and the control Progressive Addition Lens (PAL).
Measured: Comparing the 3-week wearing period at visit 4, with the 3-week wearing period at visit 3
Mean NAVQ-P score
Patient-Reported Visual Quality: change in the mean Near Visual Acuity Questionnaire Presbyopia (NAVQ-P) score, compared between the Morrow eProgressive and the control Progressive Addition Lens (PAL), reported on a scale from 0 to 3 with lower scores having a better outcome.
Measured: Comparing the 3-week wearing period at visit 4, with the 3-week wearing period at visit 3
Subjective Lens Preference for Vision
Subjective Lense Preference for Vision: the proportion of participants expressing an overall preference in terms of better vision for the Morrow eProgressive lens compared to the control Progressive Addition Lens (PAL), as evaluated by a post-wear Lens Preference Questionnaire, reported on a scale from 1 to 10 with higher scores having a better outcome.
Measured: Comparing the 3-week wearing period at visit 4, with the 3-week wearing period at visit 3
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Oct 2026
- Study start24 Sep 2026
- Primary completion28 Feb 2027 (estimated)
- Study completion28 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PresbyopiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Morrow Eyewear
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07878416
- Sponsor's protocol ID
- MRW01
- Acronym
- EPACT
- Status last verified
- Oct 2026
- First submitted
- 30 Sep 2026
- Last updated
- 16 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: This study will be registered in a public trial register (clinicaltrials.gov) prior to inclusion of the first subject. The content - including the participating Principal Investigators and Clinical Study Sites - will be updated throughout the conduct of the study. Results information from this study will be submitted to the public trial register. A study publication will be developed with the participating investigators at the end of the study.
Study at a glance
From the registry record, last updated by the sponsor on 16 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Functional Superiority of the Morrow eProgressive : A Comparative Study of Visual and Physical Comfort During Dynamic Activity
- ClinicalTrials.gov ID
- NCT07878416
- Acronym / sponsor ID
- EPACT / MRW01
- Conditions
- Presbyopia
- Keywords
- post market, presbyopia
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Morrow EyewearIndustry (pharma, biotech, devices)
- Study start
- 24 Sep 2026 (actual)
- Primary completion
- 28 Feb 2027 (estimated)
- Study completion
- 28 Feb 2027 (estimated)
- First posted
- 16 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Presbyopia is a common age-related condition where the eye loses its ability to focus on nearby objects, typically from around age 45.
The standard correction is progressive addition lenses (PALs), but these have limitations: narrow viewing zones, peripheral distortion, and the need for unnatural head movements, which can affect comfort and safety.
Morrow has developed an electronically adjustable progressive lens (Morrow eProgressive) that dynamically adapts its optical zones.
This CE-marked device is already commercially available. This study compares its functional performance against standard PALs.
Approximately 50 adults (≥45 years) will participate at three sites (Belgium and Italy). Each participant wears both glasses types for three weeks each, in random order.
Researchers will measure head and eye movements during reading tasks, stair descent performance, and visual comfort via a questionnaire. Participants will also indicate their overall lens preference.
Detailed description
Traditional PALs are characterized by fixed optical corridors bordered by lateral astigmatism. This spatial restriction imposes a significant physiological and biomechanical burden on the wearer during dynamic visual tasks. When executing lateral gaze shifts, such as shifting from the end of a line of text to the beginning of the next during reading, or scanning the ground during locomotion, wearers must either tolerate peripheral blur or employ compensatory head movements. The Morrow eProgressive utilizes active electronic focal adaptation to provide an expanded, uncompromised visual field, theoretically mitigating these optical limitations and restoring natural oculomotor patterns.
A key challenge in presbyopic clinical trials is the high degree of inter-individual variability. Factors such as individual neuro-visual adaptation speed and prior spectacle history vary widely between patients. To eliminate these significant confounding variables, this investigation utilizes a randomized, open-label, crossover design. By allowing each participant to serve as their own internal control across balanced 3-week wear periods, the study isolates the direct optical impact of the lens technology from confounding patient specific characteristics, vastly increasing the statistical validity of the intra-subject comparisons.
This study optimizes clinical efficiency by employing a dual-layered endpoint strategy:
- Objective dynamic visual performance (Primary): Eye-tracking parameter, specifically head gain, serve as objective indicator of visual field performance.
- Functional and Subjective Validation (Secondary): To ensure these micro-physiological improvements translate to real-world patient utility, objective metrics are paired with the validated Near Visual Acuity Questionnaire Presbyopia (NAVQ-P), a dedicated Subjective Lens Preference Questionnaire, and physical performance tasks via a standardized Stair Descent Test.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Morrow eProgressive | Experimental | Procedure: 3 weeks wearing of study device instead of their current wearing solution3 weeks wearing of study device instead of their current wearing solution |
| Traditional PAL | Active comparator | Procedure: 3 weeks wearing of study device instead of their current wearing solution3 weeks wearing of study device instead of their current wearing solution |
Who may qualify
- Ages
- 45 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Adults aged 45 or older, who are presbyopic in both eyes, with an inclusion criterium of minimum + 1.75 ADDition.
- Suitable candidate for Morrow glasses
- Willing and able to adhere to the study protocol and study procedures, and provide written consent prior to enrollment
- Willing and able to strictly adhere to the 2 x 3-week spectacle-wearing schedule for all standard day-to-day activities, including a commitment to exclusive progressive wear of the assigned study spectacles (traditional PAL or Morrow eProgressive) throughout each respective study phase (temporary exceptions for sports or specific occasions are permitted using single-vision solutions only).
- Current vision solution satisfaction below 8/10, as assessed by the study specific satisfaction questionnaire.
Key exclusion criteria (9 listed)
- Individuals who do not yet require a reading addition for near tasks.
- Distant BCVA worse than 20/25 (Snellen) or >0.1 LogMar
- Previous laser treatment for refractive correction.
- Any previous refraction and/or intra-ocular surgery.
- Any known systemic diseases affecting vision (e.g. diabetes, uncontrolled or unmedicated hypertension, autoimmune disease, inflammatory disease … ), at the discretion of the investigator
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 3 weeks wearing of study device instead of their current wearing solutionInstead of wearing their current solution for presbyopia, all participants can solely wear allocated spectacles during the duration of the trial for all day to day activities. | Procedure or surgery | Morrow eProgressive, Traditional PAL |
Primary outcome
Reduction in head gain
Time frame: Comparing the 3-week wearing period at visit 4, with the 3-week wearing period at visit 3
Reduction in head gain: defined as the ratio of head yaw angle to total gaze angle, assessed during optotype reading across varying horizontal and vertical gaze angles, to evaluate the superiority of the Morrow eProgressive over the control Progressive Addition Lens (PAL) in facilitating more efficient gaze strategies and dynamic visual performance.
4 secondary outcomes
Mean stair descent time
Time frame: Comparing the 3-week wearing period at visit 4, with the 3-week wearing period at visit 3
Mean cadence variability
Time frame: Comparing the 3-week wearing period at visit 4, with the 3-week wearing period at visit 3
Mean NAVQ-P score
Time frame: Comparing the 3-week wearing period at visit 4, with the 3-week wearing period at visit 3
Subjective Lens Preference for Vision
Time frame: Comparing the 3-week wearing period at visit 4, with the 3-week wearing period at visit 3
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2026.
- Individual participant dataSharing planned: No. This study will be registered in a public trial register (clinicaltrials.gov) prior to inclusion of the first subject. The content - including the participating Principal Investigators and Clinical Study Sites - will be updated throughout the conduct of the study. Results information from this study will be submitted to the public trial register. A study publication will be developed with the participating investigators at the end of the study.
Related trials for Presbyopia
Active, not recruiting
Clinical Trial With Artiflex Presbyopic (Artiplus)
Presbyopia, Ametropia
Recruiting
VisDura VisAbility™ Micro Insert System Pre-market Clinical Trial
Presbyopia
Recruiting
Volumetric Visual Fields at Intermediate and Near Distances in Presbyopic Patients Using Occupational and General-Purpose Progressive Addition Lenses
Presbyopia
Recruiting
Volumetric Visual Fields at Different Distances in Presbyopic Patients Using Occupational (PC-133 and PC-200) and General-Purpose Progressive Addition Lenses
Presbyopia
Recruiting
Proof-of-Concept for a Novel Optical Aperture Contact Lens in Presbyopia and Keratoconus
Keratoconus, Presbyopia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Research Centre in Optics & Optometry (COMiB), University of Milano Bicocca
Milan, Italy
3 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 3 weeks wearing of study device instead of their current wearing solution in people with Presbyopia, run by Morrow Eyewear at 3 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Belgium, Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reduction in head gain (time frame: Comparing the 3-week wearing period at visit 4, with the 3-week wearing period at visit 3). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2026.